CSL to buy Talecris in $3.1B deal

Looking to elbow its way to a larger share of the global plasma product market, Australia's CSL has agreed to buy Talecris Biotherapeutics for $3.1 billion. And analysts loved the deal from the minute it was announced, noting that CSL will be able to sell some assets to win regulatory approval while slicing away costs as it absorbs the U.S. company.

"Talecris is highly complementary to CSL's existing business. The acquisition will make CSL a stronger competitor in the highly competitive plasma therapeutics market place," CSL Managing Director Brian McNamee said in a statement.  

- see the Talecris release
- read the story from the Financial Times

Related Articles:
Talecris backers design a $1 billion IPO
Talecris may be sold
Talecris' antibody drug gets priority review